Personalis (NASDAQ:PSNL) Shares Down 8.4% – Should You Sell?

Personalis, Inc. (NASDAQ:PSNL) was down 8.4% during mid-day trading on Tuesday . The company traded as low as $6.10 and last traded at $6.03. Approximately 371,380 shares were traded during trading, a decline of 74% from the average daily volume of 1,425,307 shares. The stock had previously closed at $6.58.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Guggenheim upped their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Morgan Stanley lowered their target price on Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Finally, BTIG Research increased their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Personalis Price Performance

The firm’s 50 day moving average price is $7.88 and its 200-day moving average price is $8.40. The firm has a market cap of $638.66 million, a price-to-earnings ratio of -6.83 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. Analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its stake in Personalis by 273.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after acquiring an additional 7,896,714 shares during the period. ARK Investment Management LLC raised its position in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares in the last quarter. AIGH Capital Management LLC lifted its stake in Personalis by 4.5% during the third quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after purchasing an additional 168,143 shares during the period. Aberdeen Group plc boosted its holdings in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its position in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.